Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Director Betsy J. Bernard Acquires 150 Shares

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Director Betsy J. Bernard purchased 150 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was bought at an average price of $111.89 per share, with a total value of $16,783.50. Following the completion of the purchase, the director now owns 150 shares of the company’s stock, valued at $16,783.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Zimmer Biomet Stock Performance

ZBH opened at $119.23 on Wednesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.95 and a current ratio of 1.96. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.60 and a 52-week high of $149.25. The firm has a market cap of $24.91 billion, a P/E ratio of 49.47, a price-to-earnings-growth ratio of 2.31 and a beta of 1.01. The business’s fifty day moving average is $133.70 and its 200-day moving average is $131.94.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, August 1st. The medical equipment provider reported $1.82 EPS for the quarter, meeting the consensus estimate of $1.82. Zimmer Biomet had a net margin of 7.03% and a return on equity of 12.36%. The firm had revenue of $1.87 billion for the quarter, compared to analyst estimates of $1.83 billion. During the same period last year, the firm earned $1.82 EPS. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 7.51 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.81%. The ex-dividend date of this dividend is Thursday, September 28th. Zimmer Biomet’s payout ratio is presently 39.83%.

Hedge Funds Weigh In On Zimmer Biomet

Hedge funds and other institutional investors have recently modified their holdings of the business. Eubel Brady & Suttman Asset Management Inc. boosted its stake in Zimmer Biomet by 0.6% in the second quarter. Eubel Brady & Suttman Asset Management Inc. now owns 178,885 shares of the medical equipment provider’s stock valued at $26,046,000 after buying an additional 1,037 shares in the last quarter. Virginia Retirement Systems ET AL acquired a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $1,874,000. Comerica Bank bought a new stake in shares of Zimmer Biomet during the 2nd quarter valued at approximately $44,930,000. Osaic Holdings Inc. increased its position in Zimmer Biomet by 30.5% during the 2nd quarter. Osaic Holdings Inc. now owns 48,920 shares of the medical equipment provider’s stock worth $7,122,000 after purchasing an additional 11,422 shares in the last quarter. Finally, Imprint Wealth LLC bought a new position in Zimmer Biomet in the 2nd quarter valued at approximately $2,917,000. Institutional investors own 87.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on ZBH. BTIG Research raised shares of Zimmer Biomet from a “neutral” rating to a “buy” rating and set a $139.00 price objective for the company in a research report on Monday. Oppenheimer reaffirmed an “outperform” rating and issued a $157.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, August 2nd. Bank of America upgraded Zimmer Biomet from an “underperform” rating to a “neutral” rating in a research note on Wednesday, May 3rd. FIG Partners raised shares of Zimmer Biomet to a “neutral” rating in a research report on Wednesday, May 3rd. Finally, 58.com restated a “maintains” rating on shares of Zimmer Biomet in a research note on Wednesday, May 3rd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $145.16.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.